Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter

Cancer Science

Volumn 99, Issue 9, 2008, Pages 1747-1753

  Ohashi, Kadoaki ^a   Rai, Kammei ^a   Fujiwara, Yoshiro ^a   Osawa, Masahiro ^a   Hirano, Seiki ^b,c   Takata, Katsuyoshi ^a   Kondo, Eisaku ^a   Yoshino, Tadashi ^a   Takata, Minoru ^b,d   Tanimoto, Mitsune ^a   Kiura, Katsuyuki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; SURFACTANT PROTEIN C; THYROID TRANSCRIPTION FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DELETION MUTANT; DRUG EFFICACY; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HISTOPATHOLOGY; LUNG ADENOCARCINOMA; LUNG TUMOR; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; TRANSGENE; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR RESISTANCE; WILD TYPE;

ADENOCARCINOMA; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PEPTIDES; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 50149108795     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00875.x     Document Type: Article

References (42)

1. Herbst RS, Fukuoka M, Baselga J. Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 2004; 4 (12): 956-65.
2. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005; 23 (14): 3235-42.
3. Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M. Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 2003; 40 (1): 73-6.
4. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97 (5): 339-46.
5. Toyooka S, Matsuo K, Shigematsu H et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 2007; 13 (19): 5763-8.
6. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 (21): 2129-39.
7. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304 (5676): 1497-500.
8. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from 'never smokers'and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101 (36): 13306-11.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353 (2): 123-32.
10. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer -molecular and clinical predictors of outcome. N Engl J Med 2005; 353 (2): 133-44.
11. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64 (24): 8919-23.
12. Tokumo M, Toyooka S, Kiura K et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005; 11 (3): 1167-73.
13. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 64 (20): 7241-4.
14. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305 (5687): 1163-7.
15. Tang X, Shigematsu H, Bekele BN et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005; 65 (17): 7568-72.
16. Kozuki T, Hisamoto A, Tabata M et al. Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer 2007; 58 (1): 30-5.
17. Greulich H, Chen TH, Feng W et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. Plos Med 2005; 2 (11): e313.
18. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 2005; 65 (19): 8968-74.
19. Yun CH, Boggon TJ, Li Y et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11 (3): 217-27.
20. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20 (11): 1496-510.
21. Ji H, Li D, Chen L et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006; 9 (6): 485-95.
22. Korfhagen TR, Glasser SW, Wert SE et al. Cis-acting sequences from a human surfactant protein gene confer pulmonary-specific gene expression in transgenic mice. Proc Natl Acad Sci USA 1990; 87 (16): 6122-6.
23. Wang-Gillam A, Siegel E, Mayes DA et al. Anti-tumor effect of doxycycline on glioblastoma cells. J Cancer Mol 2007; 3 (5): 147-53.
24. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98 (12): 1817-24.
25. Igarashi M, Yoshida M, Watanabe M et al. Lung carcinogenesis induced by NNK in Ogg1 knockout mice. Proceedings 66th Annual Meeting of the Japanese Cancer Association.
26. Kohno T, Shinmura K, Tosaka M et al. Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 1998; 16 (25): 3219-25.
27. Kohno T, Kunitoh H, Toyama K et al. Association of the OGG1-Ser326Cys polymorphism with lung adenocarcinoma risk. Cancer Sci 2006; 97 (8): 724-8.
28. Sugimura H, Kohno T, Wakai K et al. hOGG1 Ser326Cys polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1999;8 (8): 669-74.
29. Cappuzzo F, Varella-Garcia M, Shigematsu H et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005; 23 (22): 5007-18.
30. Hirata A, Hosoi F, Miyagawa M et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 2005; 65 (10): 4253-60.
31. Fujimoto N, Wislez M, Zhang J et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005; 65 (24): 11478-85.
32. Engelman JA, Jänne PA, Mermel C et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005; 102 (10): 3788-93.
33. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005; 29 (5): 633-9.
34. Tanaka H, Yanagisawa K, Shinjo K et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007; 67 (13): 6007-11.
35. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366 (9496): 1527-37.
36. Kelly K, Chansky K, Gaspar LE et al. Updated analysis of swog 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxcel in patients with locally advaanced stage III non-small cell lung cancer. ASCO Annual Meeting Proceedings 2007.
37. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21 (12): 2237-46.
38. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352 (8): 786-92.
39. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. Plos Med 2005; 2 (3): E73.
40. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316 (5827): 1039-43.
41. Bean J, Brennan C, Shin JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104 (52): 20932-7.
42. Yamasaki F, Johansen MJ, Zhang D et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007; 67 (12): 5779-88.